Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants-Reference-Cited by-同舟云学术

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

Published:2022-08-23 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Garland Suzanne M.¹²³,Anagani Manjula⁴,Bhatla Neerja⁵,Chatterjee Sukanta⁶,Lalwani Sanjay⁷,Ross Cecil⁸,Group Thomas⁹,Lin Jianxin⁹,Luxembourg Alain⁹,Walia Anuj⁹,Tu Yingmei⁹

Affiliation:

1. Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia

2. Infection and Immunity, Murdoch Children’s Research Institute, Parkville, Victoria, Australia

3. Centre for Women’s Infectious Diseases Research, The Royal Women’s Hospital, Parkville, Victoria, Australia

4. Woman and Child Institute, CARE Super Specialty Hospital & Transplant Centre, Hyderabad, India

5. Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India

6. Department of Pediatrics, KPC Medical College & Hospital, Kolkata, India

7. Lalwani Mother & Child Care Hospital, Pune, India

8. Department of Chest Medicine & Hematology, St. John’s Medical College Hospital, Bangalore, India

9. Merck & Co., Inc., Rahway, NJ, USA

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2105067

Reference39 articles.

1. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

2. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

3. Bruni L, Albero G, Serrano B. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in India. Summary Report; 2021 Oct 14 [accessed 2022 Jan 14]. https://hpvcentre.net/statistics/reports/IND.pdf.

4. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

5. 9-Valent human papillomavirus vaccine: a review of the clinical development program

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial;The Lancet Oncology;2023-12

2. Side effects of vaccines;Side Effects of Drugs Annual;2023